Baricitinib

Systematic (IUPAC) name
	2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile
Clinical data
Legal status	Investigational;
Identifiers
CAS Number	1187594-09-7
ATC code	None
PubChem	CID: 44205240
ChemSpider	26373084
ChEMBL	CHEMBL2105759
PDB ligand ID	3JW (PDBe, RCSB PDB)
Chemical data
Formula	C16H17N7O2S
Molecular mass	371.42 g/mol
	SMILES CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3 ;
	InChI InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20) ; Key:XUZMWHLSFXCVMG-UHFFFAOYSA-N ;

Baricitinib (formerly INCB28050, LY3009104)^[1] is an oral JAK1 and JAK2 inhibitor.

Baricitinib is in Phase III development by Eli Lilly and Incyte as a potential treatment for rheumatoid arthritis (RA).^[2] Encouraging results were reported in March 2016 for refractory RA.^[3]

It is in Phase II development as a potential treatment for psoriasis and diabetic nephropathy.^{[citation needed]}

References

↑ Lua error in package.lua at line 80: module 'strict' not found.
↑ Lua error in package.lua at line 80: module 'strict' not found.
↑ Baricitinib Benefits Refractory RA - Patients had failed up to three TNF inhibitors. March 2016

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.